Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica L Mega

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Journal of Thrombosis and Thrombolysis|June 21, 2006
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapyJessica L Mega, David A Morrow, Christopher P Cannon, et al.
Journal of the American College of Cardiology|June 21, 2008
Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromesJessica L Mega, David A Morrow, James A de Lemos, et al.
The New England Journal of Medicine|November 23, 2007
Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotensionMarc S Sabatine, Kian-Keong Poh, Jessica L Mega, et al.
Journal of Thrombosis and Thrombolysis|July 18, 2013
Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trialBram J Geller, Jessica L Mega, David A Morrow, et al.
The American Journal of Cardiology|May 29, 2013
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, et al.
Global Heart|January 17, 2015
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCIGlenn N Levine, Young-Hoon Jeong, Shinya Goto, et al.
Nature Reviews. Cardiology|August 27, 2014
Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCIGlenn N Levine, Young-Hoon Jeong, Shinya Goto, et al.
Circulation|April 14, 2010
Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)Jessica L Mega, Judith S Hochman, Benjamin M Scirica, et al.
American Heart Journal|May 17, 2011
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndromeC Michael Gibson, Jessica L Mega, Paul Burton, et al.
Lancet (London, England)|August 31, 2010
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysisJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Journal of Thrombosis and Thrombolysis|June 21, 2006
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapyJessica L Mega, David A Morrow, Christopher P Cannon, et al.
Journal of the American College of Cardiology|June 21, 2008
Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromesJessica L Mega, David A Morrow, James A de Lemos, et al.
The New England Journal of Medicine|November 23, 2007
Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotensionMarc S Sabatine, Kian-Keong Poh, Jessica L Mega, et al.
Journal of Thrombosis and Thrombolysis|July 18, 2013
Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trialBram J Geller, Jessica L Mega, David A Morrow, et al.
The American Journal of Cardiology|May 29, 2013
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, et al.
Global Heart|January 17, 2015
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCIGlenn N Levine, Young-Hoon Jeong, Shinya Goto, et al.
Nature Reviews. Cardiology|August 27, 2014
Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCIGlenn N Levine, Young-Hoon Jeong, Shinya Goto, et al.
Circulation|April 14, 2010
Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)Jessica L Mega, Judith S Hochman, Benjamin M Scirica, et al.
American Heart Journal|May 17, 2011
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndromeC Michael Gibson, Jessica L Mega, Paul Burton, et al.
Lancet (London, England)|August 31, 2010
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysisJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Pageof 7